TABLE A2.
Moderna supply chain
| Company/institution | Location | Role | Key dates |
|---|---|---|---|
| Moderna | Massachusetts, US | Receives funding from Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate development of mRNA vaccine against the novel coronavirus | 23 January 2020 |
| National Institutes of Health | Maryland, US | Co‐invents the vaccine | 23 January 2020 |
| Moderna | Massachusetts, US | Manufactures vaccine for clinical trials | 23 January 2020 |
| Moderna | Massachusetts, US | Ships mRNA vaccine candidate for Phase 1 study | 24 February 2020 |
| Lonza | Basel, Switzerland | Participates in worldwide strategic collaboration | 1 May 2020 |
| Drug substance | |||
| Lonza | New Hampshire, US | Manufactures drug substance | 1 May 2020 |
| Lonza | Visp, Switzerland | Manufactures drug substance | 1 May 2020 |
| Rovi | Granada, Spain | Manufactures drug substance | 12 April 2021 |
| Moderna | Massachusetts, US | Renovates facility to expand manufacturing capacity | 4 May 2021 |
| Aldevron | North Dakota, US | Supplies plasmid DNA to serve as genetic template for mRNA vaccine | 24 May 2021 |
| Lonza | Geleen, Netherlands | Manufactures drug substance | 2 June 2021 |
| Lipid nanoparticles | |||
| CordenPharma |
Colorado, US Liestal, Switzerland Chenôve, France |
Manufactures lipids | 28 May 2020 |
| Fill and finish | |||
| Catalent | Indiana, US |
Handles fill and finish Extends contract |
25 June 2020 |
| Baxter | Indiana, US | Handles fill and finish | 8 March 2021 |
| Sanofi | New Jersey, US | Handles fill and finish | 26 April 2021 |
| Rovi | Madrid, Spain | Handles fill and finish | 9 July 2020 |
| Recipharm | Monts, France | Handles fill and finish | 30 December 2020 |
| Samsung Biologics | Incheon, South Korea | Handles fill and finish | 22 May 2021 |
| Thermo Fisher | North Carolina, US | Handles fill and finish | 1 June 2021 |
Source: Constructed by the authors. Hyperlinks provide original sources.